Immunity to thrombotic events is achievable if we stop the guessing game: Is this the major hidden message from GRAVITAS?

Thrombosis and Haemostasis

Volumn 106, Issue 2, 2011, Pages 263-264

  Gurbel, Paul A ^a   Tantry, Udaya S ^a   Bliden, Kevin P ^a   Jeong, Young Hoon ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR;

ARTICLE; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; HEART DEATH; HEART INFARCTION; HUMAN; IMMUNITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; RISK FACTOR; STENT THROMBOSIS; THROMBOCYTE ACTIVATION;

ADENOSINE DIPHOSPHATE; DRUG-ELUTING STENTS; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2Y12; THROMBOSIS;

EID: 79961092788     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-02-0064     Document Type: Article

References (6)

1. Price MJ. The GRAVITAS (Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And Safety) trial. Talk presented at the American Heart Association 2010 Scientific Sessions; November 2010, Chicago, IL, USA.
2. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834.
3. Wiviott SD, Trenk D, Frelinger AL, et al.; PRINCIPLE- TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
4. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
5. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-1199.
6. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.